vTv Therapeutics (VTVT) to Present New Small Molecule Drug Candidate Data as PD Treatment at Upcoming Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
November 16, 2016 9:05 AM ESTHIGH POINT, N.C.--(BUSINESS WIRE)-- vTv Therapeutics Inc. (vTv, Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, today announced that Dr. Bobby Thomas, Associate Professor at Medical College of Georgia, Georgia Regents University at Augusta, will present a poster at the Society for Neuroscience 2016 meeting in San Diego, featuring new pre-clinical data on a vTv small molecule drug candidate against Parkinsons disease (PD).
vTv has identified novel non-electrophilic Nrf2/Bach1 modulators that can... More
